Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications-narrative review.

BACKGROUND

Fibromyalgia affects 2%-8% of the global population with suboptimal treatment outcomes. Emerging evidence suggests histamine intolerance, mediated by diamine oxidase (DAO) deficiency, may contribute to fibromyalgia pathophysiology in specific patient subgroups.

METHODS

We conducted a comprehensive narrative review of literature published 2000-2025, examining genetic polymorphisms, biochemical markers, and clinical studies investigating relationships between histamine intolerance, DAO deficiency, and fibromyalgia. Studies included genetic association analyses, randomized controlled trials, and population-based observational research.

RESULTS

Key findings revealed 74.5% prevalence of DAO deficiency-associated genetic variants in fibromyalgia patients vs. 66% in general population (p = 0.014), with cumulative variants correlating with increased symptom severity (∼7-point FIQ increase per allele). A randomized controlled trial (n = 100) demonstrated significant improvements with DAO supplementation: Pain Catastrophizing Scale decreased 8.4 points vs. 2.1 (placebo), and Fibromyalgia Impact Questionnaire improved 12.3 vs. 4.6 points (p < 0.003). Population studies showed strong associations with histamine-mediated conditions: 29% fibromyalgia prevalence among chronic pruritus patients and odds ratios of 1.30-2.50 for allergic comorbidities among 15,869 fibromyalgia patients.

CONCLUSION

Current evidence supports systematic histamine intolerance assessment in fibromyalgia patients presenting with gastrointestinal symptoms, chronic pruritus, or treatment resistance. This review provides a practical clinical framework for identifying and managing this potentially treatable fibromyalgia subtype, though larger multicenter replication studies are needed to confirm findings and establish standardized diagnostic protocols.